Drug

ERLEADA®

Apalutamide

Erleada Overview

Erleada is a cancer medicine used to treat men with cancer of the prostate (a gland of the male reproductive system).

It is used when the cancer is not responding to treatments that lower testosterone levels and is at high risk of spreading to other parts of the body.

Erleada contains the active substance apalutamide.

Erleada is available as tablets (60 mg) to be taken by mouth. The recommended dose is 4 tablets (240 mg) a day. Treatment may be stopped temporarily and later restarted at a reduced dose if the patient experiences intolerable side effects.

Erleada can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of prostate cancer. For more information about using Erleada, see the package leaflet or contact your doctor or pharmacist.

The active substance in Erleada, apalutamide, works by blocking the action of testosterone and other male hormones known as androgens. It does this by blocking the receptors to which these hormones attach. Because prostate cancer cells need testosterone and other male hormones to survive and grow, by blocking the effects of these hormones, apalutamide slows down the growth of the cancer.

In a main study involving 1,207 patients, Erleada was shown to be more effective than placebo (a dummy treatment) at prolonging the time patients lived without the disease spreading to other parts of the body: patients on Erleada lived on average for 41 months without the disease spreading, compared with 16 months for patients taking placebo.

Erleada was shown to be effective at delaying the spread of prostate cancer that is not responding to testosterone-lowering treatments and is at high risk of spreading to other parts of the body. Although more data are needed on its effects on prolonging patients’ life, the benefits seen so far are considered important.

Regarding its safety, the side effects with Erleada were considered manageable. The European Medicines Agency therefore decided that Erleada’s benefits are greater than its risks and it can be authorised for use in the EU.

In order to further evaluate the effectiveness of Erleada, the company that markets the medicine has to submit the final results of the main study, including data on the effects of the medicine on prolonging patients’ life.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Erleada have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Erleada are continuously monitored. Side effects reported with Erleada are carefully evaluated and any necessary action taken to protect patients.

What are the risks associated with Erleada?

The most common side effects with Erleada (which may affect more than 1 in 10 people) are tiredness, skin rash, weight loss, joint pain, falls and fractures (broken bones). For the full list of side effects of Erleada.

Erleada must not be used by women who are pregnant or may become pregnant.

Owner of copyright and other intellectual property rights to European Medicines Agency

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Find more drugs

TAXOTERE® (docetaxel)

Drug TAXOTERE® Docetaxel Taxotere Overview Taxotere is a cancer medicine used to treat the following types

ERLEADA® (apalutamide)

Drug ERLEADA® Apalutamide Erleada Overview Erleada is a cancer medicine used to treat men with cancer

Cancer.cankado

At one place know the best information on various cancer drugs and common symptoms associated.

CANKADO’s PRO-react Onco helps efficient patient physician communication in the treatment phase.

© 2020 Cancer.Cankado. All rights Reserved

CANKADO is approved as an active Class I medical device within the European Union (registration number DE/CA59/11976/2017) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B.

Auto Translate »

This website uses cookies to provide their services and to analyze traffic. By using this website, you agree to use cookies.